Protease‐activated receptor‐mediated platelet aggregation in patients with type 2 diabetes on potent P2Y (12) inhibitors

BACKGROUND: Antiplatelet therapy is a cornerstone in the secondary prevention of ischemic events following percutaneous coronary intervention (PCI). The new P2Y(12) receptor inhibitors prasugrel and ticagrelor have been shown to improve patients' outcomes. Whether or not these drugs have equal...

Descripción completa

Detalles Bibliográficos
Autores principales: Panzer, Benjamin, Wadowski, Patricia P., Huber, Kurt, Panzer, Simon, Gremmel, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research: Complications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9546030/
https://www.ncbi.nlm.nih.gov/pubmed/35514270
http://dx.doi.org/10.1111/dme.14868

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9546030/
https://www.ncbi.nlm.nih.gov/pubmed/35514270
http://dx.doi.org/10.1111/dme.14868

Ejemplares similares